# Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

> **NCT03698383** · PHASE2 · UNKNOWN · sponsor: **Korean Cancer Study Group** · enrollment: 15 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab biosimilars(Herzuma), Gedatolisib

## Key facts

- **NCT ID:** NCT03698383
- **Lead sponsor:** Korean Cancer Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-03
- **Primary completion:** 2021-10
- **Final completion:** 2021-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03698383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03698383, "Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03698383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*